| abstract |
Compounds of formula (I): wherein: Q represents an optionally substituted 5- or 6-membered aryl or heteroaryl ring; X represents O, S, NR<SUP>5 </SUP>or CR<SUP>6 </SUP>R<SUP>7</SUP>; Y represents CHOH, CHSH, NOR<SUP>8</SUP>, CNR<SUP>8 </SUP>or CNOR<SUP>8</SUP>; Z represents a bond, CR<SUP>10</SUP>R<SUP>11</SUP>, O, S, SO, SO<SUB>2</SUB>, NR<SUP>10</SUP>, OCR<SUP>10</SUP>R<SUP>11</SUP>, CR<SUP>10</SUP>R<SUP>11 </SUP>O or Z, R<SUP>4 </SUP>and Q together form an optionally substituted fused tricyclic group; R<SUP>1</SUP>, R<SUP>1'</SUP>, R<SUP>3 </SUP>and R<SUP>3'</SUP> each independently represents H, C<SUB>1-6 </SUB>alkyl or C<SUB>1-4 </SUB>alkylaryl; R<SUP>2 </SUP>represents CO<SUB>2</SUB>R<SUP>8</SUP>, CONR<SUP>5</SUP>OR<SUP>9 </SUP>or NR<SUP>5</SUP>COR<SUP>9</SUP>; R<SUP>4 </SUP>represents optionally substituted 5- or 6-membered aryl or heteroaryl; R<SUP>5 </SUP>represents H or C<SUB>1-3 </SUB>alkyl; R<SUP>6 </SUP>and R<SUP>7 </SUP>each independently represents H, C<SUB>1-3 </SUB>alkyl or halo; R<SUP>8 </SUP>represents H or C<SUB>1-2 </SUB>alkyl; R<SUP>9 </SUP>represents H or C<SUB>1-3 </SUB>alkyl; R<SUP>10 </SUP>and R<SUP>11 </SUP>each independently represents H, C<SUB>1-6 </SUB>alkyl or C<SUB>1-4 </SUB>alkylaryl; and physiologically functional derivatives thereof, processes for their preparation, pharmaceutical formulations containing them and their use as inhibitors of matrix metalloproteinase enzymes (MMPs) are described. |